Want to see HK:1011 full AI Analyst Report?
1011 Stock Chart & Stats
HK$0.84
<HK$0.01(0.40%)
At close: 4:00 PM EST
HK$0.84
<HK$0.01(0.40%)
Day’s Range― - ―
52-Week RangeHK$0.34 - HK$1.35
Previous CloseN/A
Volume22.00K
Average Volume (3M)1.68M
Market Cap
HK$393.83M
Enterprise ValueHK$569.91M
Total Cash (Recent Filing)HK$7.22M
Total Debt (Recent Filing)HK$316.83M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding948,997,700
10 Day Avg. Volume1,250,790
30 Day Avg. Volume1,683,352
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-1.66
Price to Sales (P/S)18.81
P/FCF Ratio-18.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin RecoveryA jump in gross margin from ~14% to ~37% implies improved product mix, pricing or lower direct costs. This structural improvement supports longer-term margin recovery potential, enabling the company to leverage fixed costs and narrow operating losses if revenue stability continues.
Revenue ReboundA ~26% revenue increase in 2025 signals renewed commercial traction after prior declines. Durable top-line recovery can underpin scale benefits, improve fixed-cost absorption and provide a foundation for sustainable cash generation if the company maintains consistent sales execution in its specialty CNS markets.
Integrated Pharma CapabilitiesOwning or coordinating R&D, regulatory, manufacturing and commercialization creates vertical capabilities that speed product development and market launches. For a specialty CNS player, this integration raises barriers to entry, aids lifecycle management, and supports durable commercialization advantages versus pure-play distributors.
Bears Say
Negative Equity And High LeverageNegative shareholders' equity combined with very large debt exposes the company to refinancing, covenant and solvency risks. This impaired capital structure reduces strategic optionality, raises borrowing costs, and materially increases the probability that external financing or restructuring will be required to fund operations.
Chronic UnprofitabilitySustained, deep losses and very negative operating margins indicate structural issues with cost base, pricing or scale economics. Persistent unprofitability erodes capital, necessitates continual funding, and makes it difficult to demonstrate durable unit economics or justify reinvestment without material operational changes.
Inconsistent Cash GenerationReversal to negative operating and free cash flow increases dependence on external capital and heightens execution risk. Inconsistent cash generation constrains R&D and commercial spend, raises dilution or default risk, and limits the company’s ability to fund strategic initiatives without refinancing under stressed conditions.
China NT Pharma Group Co., Ltd. News
1011 FAQ
What was China NT Pharma Group Co., Ltd.’s price range in the past 12 months?
China NT Pharma Group Co., Ltd. lowest stock price was HK$0.34 and its highest was HK$1.35 in the past 12 months.
What is China NT Pharma Group Co., Ltd.’s market cap?
China NT Pharma Group Co., Ltd.’s market cap is HK$393.83M.
When is China NT Pharma Group Co., Ltd.’s upcoming earnings report date?
China NT Pharma Group Co., Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 47 days.
How were China NT Pharma Group Co., Ltd.’s earnings last quarter?
China NT Pharma Group Co., Ltd. released its earnings results on Mar 31, 2026. The company reported -HK$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.015.
Is China NT Pharma Group Co., Ltd. overvalued?
According to Wall Street analysts China NT Pharma Group Co., Ltd.’s price is currently Overvalued.
Does China NT Pharma Group Co., Ltd. pay dividends?
China NT Pharma Group Co., Ltd. pays a Annually dividend of HK$0.035 which represents an annual dividend yield of N/A. See more information on China NT Pharma Group Co., Ltd. dividends here
What is China NT Pharma Group Co., Ltd.’s EPS estimate?
China NT Pharma Group Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China NT Pharma Group Co., Ltd. have?
China NT Pharma Group Co., Ltd. has 948,997,700 shares outstanding.
What happened to China NT Pharma Group Co., Ltd.’s price movement after its last earnings report?
China NT Pharma Group Co., Ltd. reported an EPS of -HK$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.389%.
Which hedge fund is a major shareholder of China NT Pharma Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1011
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China NT Pharma Group Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.15%
12-Months-Change
Fundamentals
Return on Equity
9.46%
Trailing 12-Months
Asset Growth
8.82%
Trailing 12-Months
Company Description
China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
China Shineway Pharmaceutical Group Limited
―